Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

Key TakeawaysAn antibody treatment effectively protects babies against RSV infectionThe treatment reduced the risk of ...

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

A single-shot therapy offered to newborns in Ireland between September last and the end of February has dramatically reduced ...

With millions of cases annually worldwide, especially among infants under six months, RSV imposes a significant burden on families and healthcare systems. Current treatments are limited to ...

RSV is also a very big pie to share ... to invest £1bn in "the world's leading centre for cancer research and treatment" in a London borough.

ribavirin—an antiviral previously used for RSV treatment—showed minimal efficacy. This result highlights the limitations of ribavirin in the organoid model and suggests that newer antiviral ...

Each year, approximately 177,000 adults aged 65 and older are hospitalized in the United States due to RSV, and an estimated ...

The Lancet Child & Adolescent Health: Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis The Lancet Child & Adolescent ...